Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.

T. Yonei, T. Ohnoshi, S. Hiraki, H. Ueoka, Katsuyuki Kiura, T. Moritaka, T. Shibayama, Masahiro Tabata, Y. Segawa, N. Takigawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalActa Medica Okayama
Volume47
Issue number4
Publication statusPublished - Aug 1993

Fingerprint

Platinum
Tumor Cell Line
Tumors
Lung Neoplasms
Carboplatin
Cisplatin
Cells
Etoposide
Doxorubicin
Maximum Tolerated Dose
Small Cell Lung Carcinoma
nedaplatin
Assays
Growth
Pharmaceutical Preparations
NK 121
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yonei, T., Ohnoshi, T., Hiraki, S., Ueoka, H., Kiura, K., Moritaka, T., ... Takigawa, N. (1993). Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. Acta Medica Okayama, 47(4), 233-241.

Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. / Yonei, T.; Ohnoshi, T.; Hiraki, S.; Ueoka, H.; Kiura, Katsuyuki; Moritaka, T.; Shibayama, T.; Tabata, Masahiro; Segawa, Y.; Takigawa, N.

In: Acta Medica Okayama, Vol. 47, No. 4, 08.1993, p. 233-241.

Research output: Contribution to journalArticle

Yonei, T, Ohnoshi, T, Hiraki, S, Ueoka, H, Kiura, K, Moritaka, T, Shibayama, T, Tabata, M, Segawa, Y & Takigawa, N 1993, 'Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.', Acta Medica Okayama, vol. 47, no. 4, pp. 233-241.
Yonei T, Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Moritaka T et al. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. Acta Medica Okayama. 1993 Aug;47(4):233-241.
Yonei, T. ; Ohnoshi, T. ; Hiraki, S. ; Ueoka, H. ; Kiura, Katsuyuki ; Moritaka, T. ; Shibayama, T. ; Tabata, Masahiro ; Segawa, Y. ; Takigawa, N. / Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. In: Acta Medica Okayama. 1993 ; Vol. 47, No. 4. pp. 233-241.
@article{ff0ada85077942b9b79db5e9588a2c84,
title = "Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.",
abstract = "Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70{\%} tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.",
author = "T. Yonei and T. Ohnoshi and S. Hiraki and H. Ueoka and Katsuyuki Kiura and T. Moritaka and T. Shibayama and Masahiro Tabata and Y. Segawa and N. Takigawa",
year = "1993",
month = "8",
language = "English",
volume = "47",
pages = "233--241",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.

AU - Yonei, T.

AU - Ohnoshi, T.

AU - Hiraki, S.

AU - Ueoka, H.

AU - Kiura, Katsuyuki

AU - Moritaka, T.

AU - Shibayama, T.

AU - Tabata, Masahiro

AU - Segawa, Y.

AU - Takigawa, N.

PY - 1993/8

Y1 - 1993/8

N2 - Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.

AB - Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027650903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027650903&partnerID=8YFLogxK

M3 - Article

C2 - 8213217

AN - SCOPUS:0027650903

VL - 47

SP - 233

EP - 241

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -